Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.

Japanese firm sets stage to acquire US bioventure after it raises stake just ahead of key readout for lead asset.

Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is looking for the approval of four molecules in the coming year.